US regulators sent seemingly mixed messages this month about the outlook for animal-derived, or desiccated, thyroid medicines ...

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie has performed better than the market over the past decade. The company has lost a major product, but its lineup and ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

HORSHOLM, DENMARK / ACCESS Newswire / August 20, 2025 / Revenue and earnings for Gubra Group (CPH:GUBRA) have been record-high in the second quarter of 2025 driven by the outlicensing deal with AbbVie ...

AbbVie has announced a USD 195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

UChicago Medicine is launching a national cancer network to bring its academic medicine expertise to other communities in the ...